Core Viewpoint - The article emphasizes the importance of scaling and cost-effectiveness in the bio-manufacturing industry to compete with traditional manufacturing sectors, particularly the chemical industry, and to achieve carbon neutrality goals [6][10][12]. Group 1: Key Elements of Bio-Manufacturing - Bio-manufacturing is positioned as a manufacturing sector that aims to replace traditional industries, particularly chemicals and inorganic materials [6][10]. - The success of high-tech industries relies heavily on research and development investments, which must be supported by companies possessing core technological capabilities [6][7]. - Intellectual property protection is crucial for fostering innovation and ensuring that companies can profit from their research investments [8][9]. - The supply of raw materials is a significant challenge, as bio-manufacturing must find reliable and stable sources of biomass that do not compete with food supplies [9][10]. Group 2: Resource Factors - Current bio-manufacturing resources primarily include food crops and biomass, with high-energy raw materials like palm oil and soybeans being expensive [13][17]. - Corn is the main raw material for bio-manufacturing globally, but its use in China is limited due to population pressures [17][19]. - The industry faces challenges in utilizing agricultural waste effectively, with many attempts resulting in commercial failures [17][19]. Group 3: Cost Factors - Selecting the right projects is essential to minimize trial and error costs in bio-manufacturing [20][22]. - The bio-manufacturing industry must compete with fossil fuels, and the energy density of bio-based materials is inherently lower than that of traditional chemical products [21][22]. - The cost structure of bio-manufacturing in China is competitive due to lower labor and investment costs compared to the US and Europe [28][30]. Group 4: Market Factors - New bio-manufactured products face significant market entry challenges, including user risk perceptions and complex value chains [31][33]. - The competition is not only from peers but also from established fossil fuel industries, which dominate market standards and decision-making processes [37][38]. - There are negative perceptions about bio-manufacturing being small-scale and high-cost, which can hinder investment and market acceptance [38][40]. Group 5: Recommendations for Bio-Manufacturing in Hainan - Companies should consider competitive energy solutions and the availability of raw materials when establishing bio-manufacturing projects in Hainan [48][49]. - The government should facilitate market access for bio-manufactured products to encourage early adoption and create demonstration cases [49][50].

Core Insights - The Chinese government has included four future industries—biomanufacturing, quantum technology, embodied intelligence, and 6G—in this year's work report, highlighting their potential impact on economic development [1][2]. Industry Developments - China has made early advancements in future industries, particularly in embodied intelligence, with companies like Huawei, Tencent, BYD, and UBTECH actively investing in this sector [3][4]. - The concept of embodied intelligence, which integrates physical entities with intelligent decision-making, is gaining traction, especially following its showcase during the Spring Festival Gala [2][3]. - Biomanufacturing is being prioritized across provinces, with significant investments in green biomanufacturing technologies since 2018 [4]. - Quantum technology is also a focus, with platforms like "Kua Fu" demonstrating strong performance metrics and plans for global algorithm competitions [4]. 6G Technology - China has established the world's first 6G outdoor test network, indicating significant progress in this area [5][6]. - The transition from 5G to 6G is expected to drastically reduce download times, with projections suggesting a 1GB movie could download in just 0.03 seconds on a 6G network [6][7]. - Various regions are conducting 6G technology trials, with notable advancements in mobile video transmission and satellite communication networks [7]. Investment Mechanisms - The Chinese government is focusing on establishing a growth mechanism for future industry investments, addressing who invests, where to invest, and how to ensure effective investment [9][10]. - Cities like Shenzhen are implementing policies to facilitate technology innovation loans, with over 570 tech companies receiving a total of 17.2 billion yuan in loans [10]. - A comprehensive investment strategy is being developed to support the entire value chain of future industries, emphasizing the need for patience and long-term capital [12][13].

Group 1 - During the "May Day" holiday, construction workers in Shandong are actively working on key projects to ensure progress [1][2] - A 240-meter super high-rise complex is under construction in Qingdao, which aims to attract more shipping, trade, and financial enterprises [2] - The construction team is collaborating with Qingdao University of Technology to tackle the complex structural challenges of the project using BIM modeling and stress simulation [2][4] Group 2 - The Dongxiao Biological High-end Intelligent Health Deep Processing Project includes the construction of multiple production lines with a total capacity of 120,000 tons [3] - The project aims to produce various products, including dietary fiber and probiotics, to meet diverse customer needs [3] - The construction of the Fuxing Road project in Zaozhuang High-tech Zone is progressing, with 85% of the overall work completed [4] Group 3 - Advanced technology is being utilized on construction sites, including AI cameras and smart inspection robots, to enhance safety and efficiency [4] - The Qingdao project has introduced a "Worker Technology Service Station" for safety training, utilizing VR technology for immersive learning experiences [4]

Group 1: Investment Projects and Trends - In Q1 2025, Guangzhou signed 677 new industrial investment projects with a total expected investment of 227.49 billion yuan, including 422 high-quality projects [1] - The city has seen significant growth in domestic investment, ranking first in total investment and second in growth rate across the province [1] - Major projects in the manufacturing sector, such as a 54.9 billion yuan direct current transmission project and a new automotive technology company, are boosting development confidence [4][5] Group 2: Focus on Emerging Industries - Guangzhou is targeting strategic emerging industries like artificial intelligence and biomanufacturing through "targeted investment," aiming to attract high-tech enterprises [2] - Notable projects include the establishment of the China headquarters for Kasei Rui Biotech and the global headquarters for Micronano Robotics [2] - The digital economy is also expanding, with companies like ByteDance and Alibaba establishing significant operations in the region [2] Group 3: Foreign Investment and Global Engagement - Guangzhou has actively engaged in international investment promotion, hosting multiple delegations to countries like Spain, Japan, and Singapore [6] - The city has been recognized as China's preferred investment destination for eight consecutive years, with a 3.53% year-on-year increase in new foreign investment projects [7] - In Q1, foreign investment in the manufacturing sector reached 4.902 billion yuan, a remarkable increase of 86.8% [7] Group 4: Business Environment and Policy Innovations - Guangzhou has enhanced its business environment by integrating resources and optimizing policies to attract investments [9] - The launch of the "Guangzhou Investment Land Supermarket" allows investors to access real-time information on available land, promoting ease of investment [9] - The city has implemented various measures to streamline project approvals and reduce costs for businesses, addressing common investment challenges [9][10]

Core Viewpoint - The article highlights the financial performance of Kasei Biotech in Q1 2025, showcasing significant growth in revenue and net profit, primarily driven by the sales of long-chain dicarboxylic acids [2][4]. Financial Performance - Kasei Biotech reported a revenue of 776 million yuan in Q1 2025, representing a year-on-year increase of 13.3% [2][3]. - The net profit attributable to shareholders reached 137 million yuan, up 30.1% compared to the same period last year [2][3]. - The net profit after deducting non-recurring gains was 135 million yuan, reflecting a 31.4% increase year-on-year [2][3]. - Research and development expenses amounted to 60.55 million yuan, marking a 35.21% increase from the previous year [2][3]. Product and Market Insights - The growth in net profit is attributed to the increased sales volume and gross profit from the series of long-chain dicarboxylic acids [4]. - Long-chain dicarboxylic acids (LCDA) are gaining traction in various applications, including the production of high-performance materials and pharmaceuticals [5]. - Kasei Biotech is positioned as a leading global supplier of bio-manufactured long-chain dicarboxylic acids, capitalizing on the market shift from traditional chemical methods to more sustainable production [5]. Capacity and Future Outlook - Kasei Biotech has a production capacity of 115,000 tons per year for bio-manufactured long-chain dicarboxylic acids and other related products [7]. - The company has successfully ramped up production of new products, such as dodecanedioic acid, contributing to significant revenue growth [6].

Summary of Kaisa Biotech Conference Call Company Overview - Kaisa Biotech reported a profit increase of 33.41% in 2024, reaching 489 million yuan, with a non-recurring net profit growth of 51.6% to 465 million yuan. [2][3] - In Q1 2025, the company achieved record revenue of 776 million yuan, a year-on-year increase of 13.33%, and a net profit of 137 million yuan, up 30.11%. [2][3] Financial Performance - For 2024, Kaisa Biotech's total revenue was 2.958 billion yuan, a 39.91% increase year-on-year, with a gross profit of 924 million yuan, up 51.83%. [3] - As of the end of 2024, total assets were 19.021 billion yuan, a 1% increase from the beginning of the year, and net assets were 11.507 billion yuan, up 3.07%. [3] - R&D investment was 233 million yuan, accounting for 7.89% of revenue, a decrease of 1 percentage point year-on-year. [3] Industry Dynamics - Approximately 40% of Kaisa Biotech's revenue comes from overseas markets, with limited impact from the US-China trade war due to the nature of its products. [2][6] - The company is focusing on large-scale applications in the construction sector through collaboration with China Merchants Group, with pilot projects underway in six regions. [2][7] Strategic Partnerships - Kaisa Biotech formed a joint venture with CATL (Contemporary Amperex Technology Co., Limited) named Anhui Kaixian Times, expected to involve new energy battery technologies and materials development. [2][8] - Multiple projects in power batteries and energy storage systems are being validated, with partial production expected by the second half of 2025. [9] Product Development - The company is launching a 10,000-ton bio-based polyamide project, which began production at the end of 2024 and has started sales in 2025, receiving positive customer feedback. [2][12] - Bio-based polyamide is being developed for various applications, including vulcanizing agents and agricultural intermediates, with a focus on increasing market share domestically and internationally. [13] R&D and Innovation - Kaisa Biotech is investing in AI through a partnership with Molecular Heart to enhance R&D efficiency in biomanufacturing, focusing on protein structure prediction and metabolic pathway design. [4][23] - The company has over 20 years of experience in the industrialization of long-chain dicarboxylic acids, utilizing gene editing and AI tools to accelerate R&D and reduce costs. [4][26] Market Outlook - The demand for long-chain dicarboxylic acids remains stable, with ongoing development of new applications expected to positively impact future demand. [29] - The company is also expanding its production capacity for long-chain dicarboxylic acids and related products to meet market needs. [21][29] Additional Insights - The joint venture with China Merchants is progressing, with equipment procurement nearly complete and construction expected to be operational by the end of 2025. [11] - The company is actively working on industry standard certifications to facilitate the adoption of its new materials in various applications. [28]

【SynBioCon】 获 悉， 4月29日，中国985高校中首个合成生物学学院—— 天津大学合成生物与生物制造学院揭牌成立 ，以主动应对新型人才培养、 生物技术革命和生物制造产业变革挑战，服务国家重大战略。 新成立的合成生物与生物制造学院将整合多学科资源，用人工智能赋能教学科研，搭建全方位的人才培养与科研创新平台。 据悉， 这是我国"世界一流 建设高校"中首个合成生物学院 ，也是天津大学统筹推进教育科技人才体制机制一体改革的重要举措。学院将以建设世界一流学科为目标，不断提升教学 科研水平，助力我国在合成生物学与生物制造领域不断取得新突破，为解决国家重大战略问题和全球性问题提供创新方案，培养创新人才。 据介绍，合成生物与生物制造致力于设计、改造乃至从头构建生物体系，以应对材料、能源、环境和健康等全球性挑战。据麦肯锡预测，未来全 球60%的物质可通过生物合成生产，潜在经济价值达30万亿美元。"合成生物"被列入我国《"十四五"规划和2035年远景目标纲要》，是具有 战略性、引领性和颠覆性的未来产业。 在合成生物学科研领域，天津大学实力雄厚，拥有合成生物技术全国重点实验室、教育部"珠峰计划"合成生物学前沿科学中心， ...

【SynBioCon】 获 悉， 4月28日，主题为"技术造物 创引未来"的天津港保税区生物制造产业新闻发 布会举行。会上，天津港保税区发布了 《天津港保税区推动生物制造产业高质量发展行动方案》 （以 下简称《行动方案》）和 《天津港保税区关于支持生物制造产业高质量发展的若干政策》 （以下简 称"生物制造十条"）。 近些年，生物制造作为全新的"造物"技术，成为全球竞相布局的科技战略高地。今年政府工作报告中 提到，因地制宜发展新质生产力，培育生物制造、量子科技、具身智能、6G等未来产业。我市去年已 印发《天津市加快合成生物创新策源推动生物制造产业高质量发展实施方案》，天津港保税区按照全市 工作部署正全力打造生物制造先导区。此次发布会展现了天津港保税区生物制造产业在创新策源、成果 产业化、空间布局、人才支撑、标志性项目等方面的先发优势及推动生物制造创新成果产业化应用实 践，促进新产业、新模式、新动能加快 落地。 01 政策上新 全力打造百亿级产业集群 记者从会上获悉，《行动方案》以推动生物制造创新成果产业化应用实践为主线，因地制宜构建符合新 质生产力发展的新型生产关系，重点聚焦创新策源地、孵化转化高地和创新生态三 ...

Core Viewpoint - The company, Shengxiang Biotechnology, reported steady growth in its financial performance for 2024 and Q1 2025, with significant increases in revenue and net profit, alongside strategic acquisitions to enhance its market position in the life sciences sector [1][5]. Financial Performance - In 2024, the company achieved a revenue of 1.458 billion yuan and a net profit of 276 million yuan, both meeting expectations; the non-recurring net profit increased by 182% year-on-year [1]. - For Q1 2025, the company reported a revenue of 475 million yuan, a 22% year-on-year increase, and a net profit of approximately 91.74 million yuan, up 13% [1][5]. - The company plans to distribute a cash dividend of 2.75 yuan per 10 shares, totaling around 158 million yuan, raising the total dividend for 2024 to over 300 million yuan [1]. Strategic Acquisitions - In 2025, the company initiated a series of acquisitions, including an 807.5 million yuan purchase of 100% equity in Zhongshan Haiji, entering the biopharmaceutical growth hormone sector [5][6]. - The company also invested 75.6 million yuan for a 54% stake in Hong'an Jiyuan and 130 million yuan in Zhenmai Biotechnology to enhance its capabilities in blood cell testing and gene sequencing [6]. - These acquisitions are supported by a strong cash flow, with a net cash flow from operating activities of 274 million yuan in 2024, a 530.34% increase year-on-year [6]. Technological Advancements - In 2024, the company invested 361 million yuan in R&D, a 53% increase, representing about 25% of its revenue, and obtained over 200 new domestic and international certifications and patents [2]. - The company made significant progress in key areas such as respiratory diseases, maternal and child health, and blood source testing, with new products launched and certifications obtained [2][3]. - The company is also focusing on AI applications in healthcare, developing a smart infectious disease system that integrates cloud, IoT, big data, and AI technologies for automated detection and monitoring [3][4]. Market Expansion and Service Model - Shengxiang Biotechnology is establishing a comprehensive medical service system that integrates hospitals, communities, and home care to enhance primary healthcare capabilities [4]. - The company has launched home testing services for respiratory pathogens in multiple provinces, promoting an "Internet + Healthcare" service model [4]. - Plans for 2025 include further international market investments and a commitment to localize operations while sharing Chinese experiences along the Belt and Road Initiative [6].

山东港口青岛港前湾集装箱码头。 韩加君摄（人民视觉） 数据来源：国家统计局、国家知识产权局、交通运输部 四川成都市双流区黄水镇，95后新农人对小麦进行植保作 业。 李向雨摄（新华社发） 数据来源：国家统计局、国家知识产权局、交通运输部 4月24日，搭载神舟二十号载人飞船的长征二号F遥二十 运载火箭在酒泉卫星发射中心发射升空。 新华社记者 李 鑫摄 青年兴则国家兴，中国发展要靠广大青年挺膺担当。面对复杂严峻的外部环境，广大青年坚定信心、保 持定力，集中精力办好自己的事，不断增强做中国人的志气、骨气、底气，树立为祖国为人民永久奋 斗、赤诚奉献的坚定理想。本期报道，我们聚焦来自不同行业奋战在各自岗位的青年人，展现他们自信 自强、刚健有为，为中国式现代化挺膺担当的信念与风采。 ——编 者 青年企业家李承： 研算法，成果越研越新 9点，到研发实验室与技术团队探讨实验要点；11点，与生产基地对接业务……江苏苏州聚维元创生物 科技有限公司联合创始人李承的时间表排得满满当当。 杨铭轩是南方电网储能公司检修试验分公司自动化检修部总经理。2021年初，他接到任务，带领团队研 制全国产化抽水蓄能核心控制系统。 "长期以来，这套系统 ...